APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Lipid-lowering Agent

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Lipid-lowering Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174007810321 December 2025195 pages

Choose your research edition.

Industry ResearchLipid-lowering Agent Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Lipid-lowering Agent Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Lipid-lowering Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lipid-lowering Agent Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Lipid-lowering Agent Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Lipid-lowering Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lipid-lowering Agent include Abbott, Teva, SUN Pharma, Novartis, Merck, Pfizer, GlaxoSmithKline, Amgen and Abbvie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lipid-lowering Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lipid-lowering Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lipid-lowering Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lipid-lowering Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Lipid-lowering Agent Segment by Company

Abbott

Teva

SUN Pharma

Novartis

Merck

Pfizer

GlaxoSmithKline

Amgen

Abbvie

AstraZeneca

Torrent Pharmaceuticals

JX Pharmaceuticals

HanAll BioPharma

Cerenis Therapeutics

Aurobindo Pharma

Lipid-lowering Agent Segment by Type

Acipimox

Fibrates

Niaci

Others

Lipid-lowering Agent Segment by Application

Hospitals

Clinics

Others

Lipid-lowering Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid-lowering Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lipid-lowering Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid-lowering Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lipid-lowering Agent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lipid-lowering Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Lipid-lowering Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Lipid-lowering Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Lipid-lowering Agent Industry Trends Table 2. Lipid-lowering Agent Industry Drivers Table 3. Lipid-lowering Agent Industry Opportunities and Challenges Table 4. Lipid-lowering Agent Industry Restraints Table 5. Global Lipid-lowering Agent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Lipid-lowering Agent Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Lipid-lowering Agent Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Lipid-lowering Agent Sales Market Share by Manufacturers Table 9. Global Lipid-lowering Agent Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Lipid-lowering Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Lipid-lowering Agent Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Lipid-lowering Agent Manufacturers, Product Type & Application Table 13. Global Lipid-lowering Agent Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Lipid-lowering Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Acipimox Table 17. Major Manufacturers of Fibrates Table 18. Major Manufacturers of Niaci Table 19. Major Manufacturers of Others Table 20. Global Lipid-lowering Agent Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 22. Global Lipid-lowering Agent Sales by Type (2027-2032) & (k units) Table 23. Global Lipid-lowering Agent Sales Market Share by Type (2021-2026) Table 24. Global Lipid-lowering Agent Sales Market Share by Type (2027-2032) Table 25. Global Lipid-lowering Agent Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Lipid-lowering Agent Revenue by Type (2021-2026) & (k units) Table 27. Global Lipid-lowering Agent Revenue by Type (2027-2032) & (k units) Table 28. Global Lipid-lowering Agent Revenue Market Share by Type (2021-2026) Table 29. Global Lipid-lowering Agent Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Others Table 33. Global Lipid-lowering Agent Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 35. Global Lipid-lowering Agent Sales by Application (2027-2032) & (k units) Table 36. Global Lipid-lowering Agent Sales Market Share by Application (2021-2026) Table 37. Global Lipid-lowering Agent Sales Market Share by Application (2027-2032) Table 38. Global Lipid-lowering Agent Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Lipid-lowering Agent Revenue by Application (2021-2026) & (k units) Table 40. Global Lipid-lowering Agent Revenue by Application (2027-2032) & (k units) Table 41. Global Lipid-lowering Agent Revenue Market Share by Application (2021-2026) Table 42. Global Lipid-lowering Agent Revenue Market Share by Application (2027-2032) Table 43. Global Lipid-lowering Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Lipid-lowering Agent Sales by Region (2021-2026) & (k units) Table 45. Global Lipid-lowering Agent Sales Market Share by Region (2021-2026) Table 46. Global Lipid-lowering Agent Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Lipid-lowering Agent Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 50. North America Lipid-lowering Agent Sales by Country (2027-2032) & (k units) Table 51. Europe Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 53. Europe Lipid-lowering Agent Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Lipid-lowering Agent Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Lipid-lowering Agent Sales by Country (2027-2032) & (k units) Table 60. Global Lipid-lowering Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Lipid-lowering Agent Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Lipid-lowering Agent Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Lipid-lowering Agent Revenue Market Share by Region (2021-2026) Table 64. Global Lipid-lowering Agent Revenue Market Share by Region (2027-2032) Table 65. Abbott Company Information Table 66. Abbott Business Overview Table 67. Abbott Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Abbott Lipid-lowering Agent Product Portfolio Table 69. Abbott Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva Lipid-lowering Agent Product Portfolio Table 74. Teva Recent Development Table 75. SUN Pharma Company Information Table 76. SUN Pharma Business Overview Table 77. SUN Pharma Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. SUN Pharma Lipid-lowering Agent Product Portfolio Table 79. SUN Pharma Recent Development Table 80. Novartis Company Information Table 81. Novartis Business Overview Table 82. Novartis Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Novartis Lipid-lowering Agent Product Portfolio Table 84. Novartis Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Merck Lipid-lowering Agent Product Portfolio Table 89. Merck Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Lipid-lowering Agent Product Portfolio Table 94. Pfizer Recent Development Table 95. GlaxoSmithKline Company Information Table 96. GlaxoSmithKline Business Overview Table 97. GlaxoSmithKline Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. GlaxoSmithKline Lipid-lowering Agent Product Portfolio Table 99. GlaxoSmithKline Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Amgen Lipid-lowering Agent Product Portfolio Table 104. Amgen Recent Development Table 105. Abbvie Company Information Table 106. Abbvie Business Overview Table 107. Abbvie Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Abbvie Lipid-lowering Agent Product Portfolio Table 109. Abbvie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. AstraZeneca Lipid-lowering Agent Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Torrent Pharmaceuticals Company Information Table 116. Torrent Pharmaceuticals Business Overview Table 117. Torrent Pharmaceuticals Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Torrent Pharmaceuticals Lipid-lowering Agent Product Portfolio Table 119. Torrent Pharmaceuticals Recent Development Table 120. JX Pharmaceuticals Company Information Table 121. JX Pharmaceuticals Business Overview Table 122. JX Pharmaceuticals Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. JX Pharmaceuticals Lipid-lowering Agent Product Portfolio Table 124. JX Pharmaceuticals Recent Development Table 125. HanAll BioPharma Company Information Table 126. HanAll BioPharma Business Overview Table 127. HanAll BioPharma Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. HanAll BioPharma Lipid-lowering Agent Product Portfolio Table 129. HanAll BioPharma Recent Development Table 130. Cerenis Therapeutics Company Information Table 131. Cerenis Therapeutics Business Overview Table 132. Cerenis Therapeutics Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Cerenis Therapeutics Lipid-lowering Agent Product Portfolio Table 134. Cerenis Therapeutics Recent Development Table 135. Aurobindo Pharma Company Information Table 136. Aurobindo Pharma Business Overview Table 137. Aurobindo Pharma Lipid-lowering Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Aurobindo Pharma Lipid-lowering Agent Product Portfolio Table 139. Aurobindo Pharma Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Lipid-lowering Agent Distributors List Table 143. Lipid-lowering Agent Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Lipid-lowering Agent Product Image Figure 2. Global Lipid-lowering Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lipid-lowering Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Lipid-lowering Agent Sales (2021-2032) & (k units) Figure 5. Global Lipid-lowering Agent Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Lipid-lowering Agent Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Acipimox Image Figure 9. Fibrates Image Figure 10. Niaci Image Figure 11. Others Image Figure 12. Global Lipid-lowering Agent Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Lipid-lowering Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Lipid-lowering Agent Sales Market Share by Type (2021-2032) Figure 15. Global Lipid-lowering Agent Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Lipid-lowering Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Lipid-lowering Agent Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Lipid-lowering Agent Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Lipid-lowering Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Lipid-lowering Agent Sales Market Share by Application (2021-2032) Figure 24. Global Lipid-lowering Agent Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Lipid-lowering Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Lipid-lowering Agent Revenue Market Share by Application (2021-2032) Figure 27. North America Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Lipid-lowering Agent Sales Market Share by Country (2021-2032) Figure 29. U.S. Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Lipid-lowering Agent Sales Market Share by Country (2021-2032) Figure 34. Germany Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Lipid-lowering Agent Sales Market Share by Country (2021-2032) Figure 41. China Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Lipid-lowering Agent Sales Market Share by Country (2021-2032) Figure 49. Brazil Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Lipid-lowering Agent Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Lipid-lowering Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Lipid-lowering Agent Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Lipid-lowering Agent Revenue (2021-2032) & (US$ Million) Figure 60. North America Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Lipid-lowering Agent Revenue (2021-2032) & (US$ Million) Figure 62. Europe Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Lipid-lowering Agent Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Lipid-lowering Agent Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Lipid-lowering Agent Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Lipid-lowering Agent Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Acipimox
  • Fibrates
  • Niaci
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Abbott
  • Teva
  • SUN Pharma
  • Novartis
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Amgen
  • Abbvie
  • AstraZeneca
  • Torrent Pharmaceuticals
  • JX Pharmaceuticals
  • HanAll BioPharma
  • Cerenis Therapeutics
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lipid-lowering Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lipid-lowering Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Lipid-lowering Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Lipid-lowering Agent Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Lipid-lowering Agent Market Dynamics
  1. 2.1 Lipid-lowering Agent Industry Trends
  2. 2.2 Lipid-lowering Agent Industry Drivers
  3. 2.3 Lipid-lowering Agent Industry Opportunities and Challenges
  4. 2.4 Lipid-lowering Agent Industry Restraints
3 Lipid-lowering Agent Market by Manufacturers
  1. 3.1 Global Lipid-lowering Agent Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Lipid-lowering Agent Sales by Manufacturers (2021-2026)
  3. 3.3 Global Lipid-lowering Agent Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Lipid-lowering Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lipid-lowering Agent Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Lipid-lowering Agent Manufacturers, Product Type & Application
  7. 3.7 Global Lipid-lowering Agent Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lipid-lowering Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lipid-lowering Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lipid-lowering Agent Tier 1, Tier 2, and Tier 3
4 Lipid-lowering Agent Market by Type
  1. 4.1 Lipid-lowering Agent Type Introduction
  2. 4.1.1 Acipimox
  3. 4.1.2 Fibrates
  4. 4.1.3 Niaci
  5. 4.1.4 Others
  6. 4.2 Global Lipid-lowering Agent Sales by Type
  7. 4.2.1 Global Lipid-lowering Agent Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Lipid-lowering Agent Sales by Type (2021-2032)
  9. 4.2.3 Global Lipid-lowering Agent Sales Market Share by Type (2021-2032)
  10. 4.3 Global Lipid-lowering Agent Revenue by Type
  11. 4.3.1 Global Lipid-lowering Agent Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Lipid-lowering Agent Revenue by Type (2021-2032)
  13. 4.3.3 Global Lipid-lowering Agent Revenue Market Share by Type (2021-2032)
5 Lipid-lowering Agent Market by Application
  1. 5.1 Lipid-lowering Agent Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Lipid-lowering Agent Sales by Application
  6. 5.2.1 Global Lipid-lowering Agent Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Lipid-lowering Agent Sales by Application (2021-2032)
  8. 5.2.3 Global Lipid-lowering Agent Sales Market Share by Application (2021-2032)
  9. 5.3 Global Lipid-lowering Agent Revenue by Application
  10. 5.3.1 Global Lipid-lowering Agent Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Lipid-lowering Agent Revenue by Application (2021-2032)
  12. 5.3.3 Global Lipid-lowering Agent Revenue Market Share by Application (2021-2032)
6 Global Lipid-lowering Agent Sales by Region
  1. 6.1 Global Lipid-lowering Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lipid-lowering Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Lipid-lowering Agent Sales by Region (2021-2026)
  4. 6.2.2 Global Lipid-lowering Agent Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Lipid-lowering Agent Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Lipid-lowering Agent Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Lipid-lowering Agent Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Lipid-lowering Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Lipid-lowering Agent Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Lipid-lowering Agent Revenue by Region
  1. 7.1 Global Lipid-lowering Agent Revenue by Region
  2. 7.1.1 Global Lipid-lowering Agent Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Lipid-lowering Agent Revenue by Region (2021-2026)
  4. 7.1.3 Global Lipid-lowering Agent Revenue by Region (2027-2032)
  5. 7.1.4 Global Lipid-lowering Agent Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Lipid-lowering Agent Revenue (2021-2032)
  8. 7.2.2 North America Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Lipid-lowering Agent Revenue (2021-2032)
  11. 7.3.2 Europe Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Lipid-lowering Agent Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Lipid-lowering Agent Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Lipid-lowering Agent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Lipid-lowering Agent Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Lipid-lowering Agent Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 SUN Pharma
  14. 8.3.1 SUN Pharma Company Information
  15. 8.3.2 SUN Pharma Business Overview
  16. 8.3.3 SUN Pharma Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SUN Pharma Lipid-lowering Agent Product Portfolio
  18. 8.3.5 SUN Pharma Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Lipid-lowering Agent Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Lipid-lowering Agent Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Lipid-lowering Agent Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Lipid-lowering Agent Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Lipid-lowering Agent Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 Abbvie
  50. 8.9.1 Abbvie Company Information
  51. 8.9.2 Abbvie Business Overview
  52. 8.9.3 Abbvie Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abbvie Lipid-lowering Agent Product Portfolio
  54. 8.9.5 Abbvie Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Lipid-lowering Agent Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Torrent Pharmaceuticals
  62. 8.11.1 Torrent Pharmaceuticals Company Information
  63. 8.11.2 Torrent Pharmaceuticals Business Overview
  64. 8.11.3 Torrent Pharmaceuticals Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Torrent Pharmaceuticals Lipid-lowering Agent Product Portfolio
  66. 8.11.5 Torrent Pharmaceuticals Recent Developments
  67. 8.12 JX Pharmaceuticals
  68. 8.12.1 JX Pharmaceuticals Company Information
  69. 8.12.2 JX Pharmaceuticals Business Overview
  70. 8.12.3 JX Pharmaceuticals Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 JX Pharmaceuticals Lipid-lowering Agent Product Portfolio
  72. 8.12.5 JX Pharmaceuticals Recent Developments
  73. 8.13 HanAll BioPharma
  74. 8.13.1 HanAll BioPharma Company Information
  75. 8.13.2 HanAll BioPharma Business Overview
  76. 8.13.3 HanAll BioPharma Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 HanAll BioPharma Lipid-lowering Agent Product Portfolio
  78. 8.13.5 HanAll BioPharma Recent Developments
  79. 8.14 Cerenis Therapeutics
  80. 8.14.1 Cerenis Therapeutics Company Information
  81. 8.14.2 Cerenis Therapeutics Business Overview
  82. 8.14.3 Cerenis Therapeutics Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Cerenis Therapeutics Lipid-lowering Agent Product Portfolio
  84. 8.14.5 Cerenis Therapeutics Recent Developments
  85. 8.15 Aurobindo Pharma
  86. 8.15.1 Aurobindo Pharma Company Information
  87. 8.15.2 Aurobindo Pharma Business Overview
  88. 8.15.3 Aurobindo Pharma Lipid-lowering Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aurobindo Pharma Lipid-lowering Agent Product Portfolio
  90. 8.15.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lipid-lowering Agent Value Chain Analysis
  2. 9.1.1 Lipid-lowering Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lipid-lowering Agent Production Mode & Process
  6. 9.2 Lipid-lowering Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lipid-lowering Agent Distributors
  9. 9.2.3 Lipid-lowering Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst